Larimar Therapeutics Q2 net loss $8.4M; FDA clears 50 mg cohort and OLE trial for CTI-1601 in FA

Larimar Therapeutics, Inc.

2023-Q2 EPS reported -$0.34

Net loss of $8.4M (-$0.19/share) vs $8.7M in Q2 2022; cash $104.2M, runway into Q4 2024.
FDA cleared initiation of 50 mg cohort in Phase 2 FA trial and Open-Label Extension after review of 25 mg data.
Top-line data from 25 mg cohort showed CTI-1601 was well-tolerated and increased frataxin levels from baseline.
New CMO appointed: Russell Clayton, DO, replaces retired Nancy Ruiz.
Expect top-line 50 mg data in 1H 2024; OLE interim data in Q4 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Larimar Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income $8.4 million, or $0.19 per share, EPS $0.19 per share.

Period: the second quarter ended June 30, 2023
Net income: $8.4 million, or $0.19 per share
EPS: $0.19 per share
Result: reported results

Exact text from the filing

The Company reported a net loss for the second quarter of 2023 of $8.4 million, or $0.19 per share, compared to a net loss of $8.7 million, or $0.47 per share, for the second quarter of 2022.

View on SEC.gov

Browse all earnings releases →

Larimar Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-040946

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.